Milestone Pharmaceuticals Disclosed Resubmission Of New Drug Application For Etripamil For Treatment In Paroxysmal Supraventricular Tachycardia
Milestone Pharmicals披露重新提交了用於治療陣發性室上性心動過速的依曲帕米的新藥申請
Milestone Pharmaceuticals Disclosed Resubmission Of New Drug Application For Etripamil For Treatment In Paroxysmal Supraventricular Tachycardia
Milestone Pharmicals披露重新提交了用於治療陣發性室上性心動過速的依曲帕米的新藥申請
使用瀏覽器的分享功能,分享給你的好友吧